An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Palena, Claudia ^a   Fernando, Romaine I ^a   Hamilton, Duane H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anticancer vaccines; Brachyury; EMT; Metastasis; Therapeutic resistance

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT VACCINE; T BOX TRANSCRIPTION FACTOR; TUMOR ANTIGEN; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL POLARITY; CROSS PRESENTATION; DENDRITIC CELL; DRUG EFFICACY; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE RESPONSE; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

EID: 84899099742     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27220     Document Type: Article

References (10)

1. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011; 27:347-76; PMID:21740232; http://dx.doi.org/10.1146/annurev-cellbio-092910-154036.
2. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-54; PMID:12189386; http://dx.doi.org/10.1038/nrc822.
3. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009; 106:13820-5; PMID:19666588; http://dx.doi. org/10.1073/pnas.0905718106.
4. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 2010; 120:533-44; PMID:20071775; http://dx.doi. org/10.1172/JCI38379.
5. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 2011; 71:5296-306; PMID:21653678; http://dx.doi.org/10.1158/0008-5472.CAN-11-0156.
6. Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena C. The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death Dis 2013; 4:e682; PMID:23788039; http://dx.doi. org/10.1038/cddis.2013.208.
7. Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C. An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Mol Cancer Ther 2013; 12:1805-15; PMID:23783250; http://dx.doi. org/10.1158/1535-7163.MCT-12-1007.
8. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 2007; 13:2471-8; PMID:17438107; http://dx.doi.org/10.1158/1078-0432.CCR-06-2353.
9. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton D, Huang B, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res 2012; 18:3868-79; PMID:22611028; http://dx.doi.org/10.1158/1078-0432.CCR-11-3211.
10. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 2013; 4:1777-90; PMID:24125763.